Roble, Belko & Company, Inc Abb Vie Inc. Transaction History
Roble, Belko & Company, Inc
- $629 Million
- Q4 2024
A detailed history of Roble, Belko & Company, Inc transactions in Abb Vie Inc. stock. As of the latest transaction made, Roble, Belko & Company, Inc holds 5,156 shares of ABBV stock, worth $923,439. This represents 0.15% of its overall portfolio holdings.
Number of Shares
5,156
Previous 4,456
15.71%
Holding current value
$923,439
Previous $880,000
4.09%
% of portfolio
0.15%
Previous 0.14%
Shares
15 transactions
Others Institutions Holding ABBV
# of Institutions
4,129Shares Held
1.29BCall Options Held
17MPut Options Held
15M-
Vanguard Group Inc Valley Forge, PA173MShares$31 Billion0.55% of portfolio
-
Black Rock Inc. New York, NY136MShares$24.4 Billion0.54% of portfolio
-
State Street Corp Boston, MA79.6MShares$14.3 Billion0.57% of portfolio
-
Jpmorgan Chase & CO New York, NY51.8MShares$9.27 Billion0.75% of portfolio
-
Morgan Stanley New York, NY39.7MShares$7.11 Billion0.51% of portfolio
About AbbVie Inc.
- Ticker ABBV
- Exchange NYSE
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 1,768,099,968
- Market Cap $317B
- Description
- AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...